WORLD – As the world goes digital and technology continues to advance, integration of vital services into the digital world is also taking shape and healthcare is top in the list as at current owing to the pandemic.
According to a report by Grand View research, the global digital health market size was valued at USD 96.5 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 15.1% from 2021 to 2028.
The report also noted that, increasing cases of obesity, high prevalence of chronic diseases, such as diabetes, Cardiovascular Disorders (CVDs), growing need for remote patient monitoring services, and increasing patient engagement & connectivity owing to high adoption of digital health technology are the major factors promoting the market growth.
Norvartis, BioMerieux, a number of nations globally and other notable pharmaceutical companies are joining in on the party as the digital age progresses to newer heights.
Novartis recently announced a collaboration between them and Hewlett Packard Enterprise (HPE) with an agenda to accelerate the use of data and digital technologies to reimagine global health and improve access to healthcare and medicines.
The collaboration will focus on three global health enablers: identifying and integrating complex data sources related to health; advancing the application of artificial intelligence, machine learning and geo-spatial analytics to these data; and expanding access to technology in remote and underserved locations.
According to World Health Organization, Dengue fever is among the top ten global health threat and estimates that over 3.9 billion people in over 129 countries are at risk of contracting the disease, the partnership will seek to develop a disease surveillance solution for dengue fever, initially focusing on India.
Together, Novartis and HPE aspire to help remediate the growing threat of dengue fever by developing publicly available insights to help authorities proactively deploy response strategies targeting at-risk populations.
The resulting real-world evidence will complement the drug-discovery efforts of the Novartis Institute for Tropical Diseases, which is dedicated to finding new medicines to treat neglected, infectious diseases including Dengue fever.
BioMerieux, another pharma company venturing into tech, launched, EPISEQ® SARS-COV-2 a new application, intended to identify SARS-CoV-2 variants using samples from positive patients that automatically updates each week to identify variants based on international nomenclatures including any new variant of concern (VOC).
EPISEQ® SARS-COV-2 will be compatible with three major sequencing platforms (Illumina, Oxford Nanopore, Thermo Fisher) and will be easy to use by any microbiology lab without bioinformatics knowledge or computing resources.
In Dubai, the Ministry of Health and Prevention (MoHAP) and the Emirates Health Services (EHS) have launched the International Telemedicine Service, which falls within their plans to develop the Visiting Consultants Programme and help patients and doctors get remote 2nd opinion consultations in critical conditions.
The innovative service aligns the rules and regulations with the UAE constitution on providing telemedicine services included in Cabinet Resolution No. (40) of 2019 concerning the Executive Regulation of Federal Decree-Law No. (4) of 2016.
It also comes as part of the ministry’s and EHS’s vision to provide comprehensive and integrated healthcare services that are aligned with the precautionary and preventive measures in health facilities as well as improving patient’s quality of life throughout the onset of the COVID pandemic as well.
The rising adoption of digital health services during the pandemic is increasing the safety of both healthcare providers and patients, as it eliminates in-person appointments and further increases the provider capacity and the world fully maximize the use of tech in Healthcare.
